Imbria Pharmaceuticals, Inc. is a biotechnology company developing therapies for cardiometabolic diseases, focusing on advancing their lead product candidate for non-obstructive hypertrophic cardiomyopathy.

City Therapeutics is a biopharmaceutical company focused on developing RNA interference-based medicines using engineered small interfering RNAs to target a broad range of diseases.